| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 6,528 | 5,118 | ||
| General and administrative | 3,649 | 4,132 | ||
| Total operating expenses | 10,177 | 9,250 | ||
| Operating loss | -10,177 | -9,250 | ||
| Interest expense - royalty agreement | -1,510 | -1,354 | ||
| Interest expense - convertible notes payable | 0 | 0 | ||
| Fair value adjustments on derivative liabilities - royalty agreement | -82 | -118 | ||
| Fair value adjustments on convertible notes payable | 0 | - | ||
| Fair value adjustments on derivative liabilities - contingent value right agreement | -238 | - | ||
| Interest income (expense), net | 628 | 690 | ||
| Other income (expense), net | 34 | 561 | ||
| Loss before income taxes | -11,345 | -9,471 | ||
| Income tax benefit (expense) | 0 | 0 | ||
| Net loss | -11,345 | -9,471 | ||
| Less cumulative series d preferred dividends | 0 | 0 | ||
| Loss attributable to common stockholders | -11,345 | -9,471 | ||
| Foreign currency translation gain | 215 | -108 | ||
| Comprehensive loss | -11,130 | -9,579 | ||
| Basic (in shares) | 11,064,282 | 11,052,741 | ||
| Diluted (in shares) | 11,064,282 | 11,052,741 | ||
| Us-gaap_earningspersharebasic | -1.03 | -0.86 | ||
| Us-gaap_earningspersharediluted | -1.03 | -0.86 | ||
PALVELLA THERAPEUTICS, INC. (PVLA)
PALVELLA THERAPEUTICS, INC. (PVLA)